Also, previous studies have reported that this type of in-frame fusion to exon 20 of ALK generates an oncogenic protein, which suggests that this oncogenic protein is a possible therapeutic target of ALK inhibitors irrespective of cancer type.4,8,27,28 The positive ALK IHC staining in the tumor cells of our patient with parotid adenocarcinoma and the response to ALK inhibitors suggest that this fusion was an oncogenic driver. The gene discussed is ALK; the disease is neoplasm.